Plain-English translation of NCT07297173 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial for people with relapsed or refractory leukemia — meaning their cancer has returned or no longer responds to standard treatment. The trial tests a two-step approach: first, chemotherapy combined with infusion of immune cells (called G-CSF mobilized peripheral blood mononuclear cells) from a donor to reduce the leukemia burden, followed by a stem cell transplant from a matched or partially matched donor. The goal is to see if this combination approach is safe and effective at controlling the cancer.
Leukemia that comes back or stops responding to treatment is very difficult to cure with standard therapies alone. Stem cell transplants can help, but preparing the patient and improving the chances of success requires new approaches. This trial is testing whether adding immune cells before the transplant can improve outcomes and help more patients survive.
You likely qualify if…
You likely don't qualify if…
You would first receive standard chemotherapy at the trial center, followed by an infusion of immune cells collected from your donor. After this initial phase, you would receive a stem cell transplant from either the same donor or an alternative matched donor, depending on the trial protocol. You would be closely monitored for side effects and treatment response, particularly in the 100 days following the transplant, with follow-up visits to assess your recovery, survival, and disease status over 1–2 years.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China